设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2018 年第 6 期 第 13 卷

缺血后适应对急性心肌梗死直接经皮冠状动脉介入术后非罪犯血管病变进展的抑制作用

Preventive effect of ischemic postconditioning on non-culprit lesion progression in patients with acute myocardial infarction after primary percutaneous coronary intervention

作者:王健黄彦生魏经汉柳景华王韶屏张铭郑斌王长华

英文作者:Wang Jian Huang Yansheng Wei Jinghan Liu Jinghua Wang Shaoping Zhang Ming Zheng Bin Wang Changhua

单位:100029首都医科大学附属北京安贞医院心内二十八病房(王健、柳景华、王韶屏、张铭、郑斌、王长华);450003郑州,河南省人民医院心内科(黄彦生);450003郑州大学第一附属医院心内科(魏经汉)

英文单位:The 28th Ward Department of Cardiology Beijing Anzhen Hospital Capital Medical University Beijing 100029 China(Wang J Liu JH Wang SP Zhang M Zheng B Wang CH); Department of Cardiology Henan Provincial People′s Hospital Zhengzhou 450003 China(Huang YS); Department of Cardiology the First Affiliated Hospital of Zhengzhou University Zhengzhou 450003 China(Wei JH)

关键词:急性ST段抬高型心肌梗死;非罪犯血管;经皮冠状动脉介入;缺血后适应

英文关键词:ST-segmentelevationmyocardialinfarction;Non-culpritlesion;Percutaneouscoronaryintervention;Ischemicpostconditioning

  • 摘要:
  • 【摘要】目的    探讨缺血后适应对急性ST段抬高型心肌梗死(STEMI)患者直接经皮冠状动脉介入(PCI)治疗后非罪犯血管病变进展的抑制作用。方法    连续入选2010年1月至2013年12月在首都医科大学附属北京安贞医院成功接受罪犯血管直接PCI治疗的急性STEMI患者200例,应用随机数字表分为2组,各100例,缺血后适应组在导丝通过闭塞病变到达血管远端后,送球囊至闭塞处以小压力扩张球囊,开通血管后迅速关闭30 s,随后扩张球囊再灌注30 s,反复通过球囊低气压充气/放气至少4个循环;对照组不进行缺血后适应。临床随访12个月,观察2组患者因非罪犯血管病变进展再次PCI情况,以及2组患者的临床特征。结果    200例患者均完成临床及造影随访。缺血后适应组术后12个月内因非罪犯血管病变进展行再次PCI率低于对照组[7.0%(7/100)比21.0%(21/100)],差异有统计学意义(P<0.01)。根据术后12个月随访情况将2组患者分为对照随访正常组(A组,79例)、对照随访因非罪犯血管病变进展行再次PCI组(B组,21例)、缺血后适应随访正常组(C组,93例)、缺血后适应随访因非罪犯血管病变进展行再次PCI组(D组,7例),血清肾上腺素、去甲肾上腺素水平B组高于A组,D组高于C组,差异均有统计学意义(均P<0.001)。A、B、C、D组患者非罪犯血管病变基线病变类型比较差异均无统计学意义(均P>0.05)。随访正常组(172例)血清肾上腺素、去甲肾上腺素和C反应蛋白水平均低于再次PCI组(28例)[(223±48)ng/L比(309±52)ng/L,(1 807±365)ng/L比(2 528±421)ng/L,(18±6)mg/L比(24±8)mg/L],差异均有统计学意义(均P<0.001)。结论    急性STEMI患者直接PCI术后的再次血管重建部分是非罪犯血管病变进展所致,缺血后适应可能会抑制非罪犯血管病变进展。

  • 【Abstract】Objective    To investigate the preventive effect of ischemic postconditioning on non-culprit lesion progression in patients with acute ST-segment elevation myocardial infarction(STEMI) after primary percutaneous coronary intervention(PCI). Methods    A total of 200 STEMI patients undergoing primary PCI from January 2010 to December 2013 in Beijing Anzhen Hospital, Capital Medical University were randomly divided into ischemic postconditioning group and control group, with 100 cases in each group. Postoperative recovery, non-culprit lesion progression and related clinical indicators were analyzed. Results    Secondary PCI rate of non-culprit lesion in 12 months after operation in ischemic postconditioning group was significantly lower than that in control group[7.0%(7/100) vs 21.0%(21/100)](P<0.01).Seventy-nine patients did not have reoperation(group A) and 21 patients had secondary PCI(group B) in control group; 93 patients did not have reoperation(group C) and 7 patients had secondary PCI(group D) in ischemic postconditioning group. Serum levels of adrenaline and noradrenaline in group B were significantly higher than those in group A; levels of adrenaline and noradrenaline in group D were significantly higher than those in group C(P<0.001). Types of non-culprit lesion showed no significant difference among group A, B, C and D(P>0.05). Serum levels of adrenaline, noradrenaline and C-reactive protein in patients without reoperation(n=172) were significantly lower than those in patients with secondary PCI(n=28)[(223±48)ng/L vs (309±52)ng/L, (1 807±365)ng/L vs (2 528±421)ng/L, (18±6)mg/L vs (24±8)mg/L](P<0.001). Conclusions    Revascularization after primary PCI is related to non-culprit lesion progression in patients with STEMI. Ischemic postconditioning may prevent non-culprit artery lesion progression.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭